Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866

Article  CAS  PubMed  Google Scholar 

International collaboration of trialists (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177

Article  PubMed Central  Google Scholar 

Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group (2022) Adjuvant chemotherapy for muscle invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomized controlled trials. Eur Urol 81:50–61

Article  Google Scholar 

Galsky MD, Pal SK, Chowdhury S et al (2015) Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121:2586–2593

Article  CAS  PubMed  Google Scholar 

Zargar H, Shah JB, van Rhijn BW et al (2018) Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy. J Urol 199:1452–1458

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Jacobus S, Bellmunt J et al (2014) Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 32:1882–1894

Article  Google Scholar 

Plimack ER, Hoffman-Censits JH, Viterbo R et al (2014) Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 32:1895–1901

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfister C, Gravis G, Flechon A et al (2021) Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG-AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol 79:214–221

Article  CAS  PubMed  Google Scholar 

Pfister C, Gravis G, Flechon A et al (2022) Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol 40:2013–2022

Article  CAS  PubMed  Google Scholar 

Pfister C, Gravis G, Flechon A et al (2023) Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle invasive bladder cancer (VESPER): survival endpoints in an open-label, randomized, phase 3 study. Lancet Oncol S1470–2045(23):00587–00589. https://doi.org/10.1016/S1470-2045(23)00587-9

Article  Google Scholar